* Q&A with CEO Evy Lundgren-Åkerlund * Strong support for advancing XSTEM in OA * We reiterate our fair value of SEK 1.43 per share
ANNONS
Xintela recently announced promising interim data from its phase I/IIa study with XSTEM in knee osteoarthritis (OA). Data from 24 patients in all three dose levels have been analysed, 18 months after treatment. No serious safety or tolerability issues were recorded in the study and the company also received promising early efficacy data. Västra Hamnen contacted CEO Evy Lundgren-Åkerlund for a comment.